Next Digital Health (A Wi4 Initiative)’s Post

ShiraTronics Secures $66M to Advance Novel Therapy for Migraine MedTech startup ShiraTronics, Inc. has secured $66 million in Series B funding round to advance implantable neuromodulation device for treatment-resistant migraine to FDA-approved pivotal clinical trials, the company announced last Wednesday. Co-founded in 2018 by Mudit K. Jain, PhD, CEO and partner at Treo Ventures, ShiraTronics leverages advanced technologies to develop an effective therapy for chronic migraines. The company’s series B round was led by a new investor Norwest Venture Partners, with notable contributions from Seroba., the Global BioAccess Fund, and OSF HealthCare, alongside other undisclosed strategic investors. The round also saw the participation of existing investors Amzak Health, U.S. Venture Partners, Aperture Venture Partners, and Treo Ventures. Read more: https://lnkd.in/gjxksabM #fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #MedicalDevice #MigraineTreatment #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal

We’re excited to share Mesh Bio’s recent US$3.5 million Series A fundraising round, led by East Ventures alongside participation from SEEDS Capital, co-investor elev8.vc, Selvedge Venture and other existing shareholders. The funding will be allocated to further the development of Mesh Bio's digital twin technologies for managing chronic diseases and to expand its services across Southeast Asia. In this region, noncommunicable diseases (NCDs) or chronic diseases, such as cardiovascular ailments and diabetes, account for 62% of all deaths, affecting approximately nine million individuals. Mesh Bio is driven by its vision of providing state-of-the-art digital solutions to tackle the complexities of patient management and the escalating prevalence of chronic diseases. We wish Mesh Bio continued success in pioneering cutting-edge digital solutions to enhance patient care and combat the rising prevalence of chronic diseases! 🩺 #funding #venturecapital #startup #fundraising #biomedical #healthcare #medtech

📣📣📣 Applications are open for the next Medtech Accelerator program in partnership with incredible industry leaders - Baxter International Inc., GE HealthCare, and Endeavor Health. 8 to 10 teams will be selected to receive 💵 $142.5K cash investment to support the advancement of their technology and growth of their company. Plus over two years of support and access to mHUB - the nation's leading hardtech incubator and manufacturing entrepreneurship company - and the opportunity to secure an additional $300K+ in funding from industry partners for underwriting trials, investment, etc. Apply today by visiting - https://lnkd.in/gkxDh57U We are seeking the top companies from around the world creating unique market opportunities across: 💡Robotic or automated healthcare devices 💡Chronic disease management tools 💡Connected therapeutic devices 💡Surgical instruments 💡Detect acute or chronic conditions 💡Minimally invasive monitoring 💡Medical Devices 💡Improve drug delivery methods DM me if you have questions or would like to connect with the programs Executive Director Monica Vajani and mHUB Ventures Managing Partner Melissa Rabin Lederer or a current portfolio company. #hardtech #medtech #entreprenuership #accelerator #venture #impacthumanity

Karius has secured $100m in Series C funding, with the investment round co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, and joined by new investor Seventure Partners and existing investor SoftBank Investment Advisers, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Partners, and others. Bloomberg News' Sarah McBride reports on how the funding allows Karius to address the rising demand from healthcare providers to expand access to the #KariusTest beyond the hospital setting. Additionally, it will facilitate research into the broader health implications of Karius' #mcfDNA technology beyond infectious diseases. #funding #biotech #healthcare https://lnkd.in/eSg_jN6Y

𝗙𝗩𝗖 𝗜𝗡𝗩𝗘𝗦𝗧𝗦 𝗜𝗡𝗧𝗢 𝗗𝗘𝗘𝗣𝗧𝗘𝗖𝗛 / 𝗕𝗜𝗢𝗠𝗘𝗗𝗧𝗘𝗖𝗛 𝗧𝗢 𝗘𝗡𝗔𝗕𝗟𝗘 𝗔𝗟𝗟 𝗧𝗢 𝗕𝗥𝗘𝗔𝗧𝗛𝗘 𝗘𝗔𝗦𝗜𝗘𝗥 𝗜𝗡 𝗔 𝗚𝗥𝗘𝗘𝗡 𝗙𝗨𝗧𝗨𝗥𝗘 The Stethoscope - it's a quintessential symbol of the medical profession (since its advent in 1816), due to the all-important functions of monitoring the health of internal organs such as the heart, bowels, and the lungs. And the importance of lung health (and breathing well!) was front and centre of everyones' lives during the recent global pandemic. 👀 There's also an urgent need to improve respiratory diagnostics/monitoring, especially for community/remote health settings and other health conditions (where repeated measurements are needed). We reckon, that #AeviceHealth is the key to greater lung health in the digital age. Farquhar VC (FVC) is privileged to participate in the latest Seed-Plus round of Aevice Health (led by cofounders Adrian Ang and Rex X. Tan), where we invested alongside Coronet Ventures (led by Nirdesh K Gupta, PhD and Colin Tan), the venture affiliate of Cedars-Sinai. Other key investors include East Ventures (a juggernaut in Indonesia!), A&D Company (a world leader in #precision measurement equipment), and SEEDS Capital (the investment arm of Enterprise Singapore). Congrats Adrian, Rex, Karen, and the team. Special shoutout to The Business Times' Hykel Quek for being among the first to report on the happy news! https://lnkd.in/gFfnhS94 𝙄𝙣𝙩𝙚𝙧𝙚𝙨𝙩𝙞𝙣𝙜 𝙨𝙞𝙙𝙚𝙛𝙖𝙘𝙩:  (as a FVC portfolio startup), Aevice is... - our 𝟭𝘀𝘁 startup that's also a portfolio of NTUitive (led by CEO David Toh) - our 𝟮𝗻𝗱 startup that's also a A*STAR - Agency for Science, Technology and Research #deeptech spinoff (we're blessed to be neighbours and friends of A*StartCentral!);  - our 𝟯𝗿𝗱 startup that we have the honour of sharing the captable with SEEDS Capital; - our 𝟰𝘁𝗵 startup that has undergone #acceleration in North Asia via the Ministry of SMEs and Startups, Republic of Korea - KISED (Korea Institute of Startup & Entrepreneurship Development) K-Startup Grand Challenge ; - our 𝟱𝘁𝗵 startup that we've coinvested alongside with East Ventures (led by Pak Willson Cuaca)

mHUB is currently recruiting for its next MedTech Accelerator cohort. Applications will close on September 12, 2024. The program will commence in Chicago this November. This cohort is supported by strategic industry partners Baxter International Inc., Endeavor Health, and GE Healthcare. The mHUB MedTech Accelerator is a six-month, hands-on startup accelerator focused on the product development and commercialization of early-stage, high-potential hardtech startups. Each cohort supports 8-10 demand-driven, early-stage startups for direct investment, product development and prototyping, mentorship, business modeling, and piloting. The program and its supporting partners are seeking demand-driven, novel medical device technologies in chronic disease management, disease detection, robotic or automated devices, connected therapeutic devices, minimally invasive monitoring, improved drug delivery methods, surgical instruments, and more. Participants will receive a $200K initial investment through mHUB Product Impact Fund - $142.5K cash and $60K in in-kind benefits - on a pre-money SAFE in exchange for 6.5% equity. Learn more or apply here: https://lnkd.in/e8PrYXuC #chicago #illinois #startups #startup #prototype #smallbusiness #business #hardtech #techstartup

2024 is set to be a pivotal year for digital health startups. I sit on two startup boards (one in medtech and one in dental software) and both are doing amazing things that will advance their respective areas. They is still money available and interested buyers both strategic and sponsor! Subscribe to Medtech Strategist for a solid breakdown of the landscape and expert insight. #Medtech #MedicalDevices #DigitalHealth

Swedish #heartfailure startup Acorai closes €4.1 million to change the paradigm on acute care settings. Helsingborg-based Acorai, a startup medical device manufacturer from Sweden, has announced closing an oversubscribed €4.1 million seed round led by Solardis Health Ventures, with participation from KHP Ventures, Carma Fund and other US investors. Significant follow-on investment was taken from existing investors from across Sweden and the EU. The capital will help to finance its clinical studies and move towards regulatory approval, which comes off the back of €2.3 million in non-dilutive grant and €10 million in future equity financing from the European Innovation Council (EIC). https://lnkd.in/en94zYpq #digitalhealth #heartdisease #cardiovascularhealth

We are thrilled to share that Mesh Bio has successfully raised a $3.5 million Series A financing round, led by East Ventures, and continued support from elev8.vc, SEEDS Capital, Selvedge Venture and other existing shareholders. Southeast Asia presents myriad unmet healthcare needs, and our focus is to address these gaps effectively. With East Ventures' support, we are poised to support the rapid digital transformation of healthcare systems in this region to improve lives. We deeply appreciate their belief in our mission and commitment to healthcare innovation. This funding marks a new chapter for us. It sets the stage for us to scale our reach, embark on new developments to expand the opportunities for our HealthVector foundational digital twin model, and, most importantly, deepen our impact on health outcomes. To our community, customers, and collaborators – we are just getting started. The road ahead is filled with opportunities for #predictiveanalytics and #digitaltwins to make an impact to patient care! https://lnkd.in/gnWWFE5p

Medtech IPOs on the Move Sunnyvale-based CeriBell made headlines as it went public on Friday with a rare IPO for a medical device company, signaling a potential revival for medtech IPOs. Known for its seizure-detection headband designed to speed up diagnosis in hospitals, CeriBell's successful debut is encouraging for venture capitalists, who have faced a tough IPO market for medtech startups in recent years. CeriBell’s system, which launched in 2018, includes an AI-driven seizure detection algorithm that has gained traction in emergency departments and intensive-care units. Its solution aims to address the challenges of non-convulsive seizures, which lack visible symptoms but can result in severe outcomes if untreated. The device allows nonspecialized healthcare staff to set up EEG monitoring quickly, providing neurologists with crucial data through a user-friendly platform. This successful listing could set a positive precedent for other medtech companies, potentially revitalizing the IPO pathway for growth-stage companies. As venture firms and investors watch closely, the CeriBell IPO could signal renewed interest in medtech firms aiming for expansion and market impact.